Metastatic Melanoma Market is Projected to Grow During the Forecast Period (2023-2032) - Estimates DelveInsight | Iovance (AMTAGVI/ lifileucel), Evaxion, InxMed, AiVita Biomedical, Viralytics, Merck, BioNTech, Bristol-Myers Squibb, Cytovation

As per DelveInsight, the Metastatic Melanoma Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Melanoma, the increase in the research and development programs related to melanoma, and the launch of new therapies in the market.

DelveInsight's "Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Melanoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Metastatic Melanoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic Melanoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Metastatic Melanoma: An Overview
Melanoma is a common skin cancer that arises from the melanin cells within the upper layer of the skin (epidermis) or from similar cells that may be found in moles (nevi). This type of skin cancer may send down roots into deeper layers of the skin, and some of these microscopic roots may spread (metastasize), causing new tumor growths in vital organs of the body.

In the early stages, most melanomas do not produce any specific symptoms. Later they may appear as lesions that do not heal or an existing mole that shows changes in size or color.

The exact cause of malignant melanoma is unknown. Excessive exposure to the sun, particularly before puberty, and living in areas that are closer to the sun (i.e., tropical climates) increases the risk of developing skin cancer. A defective gene known as CDK4 has been identified and may be associated with an increased risk for familial malignant melanoma.

Melanoma typically falls into one of three general categories, i.e., cutaneous, mucosal, and ocular. Cutaneous melanoma is the most common of these categories, and is traditionally classified into primary and metastatic; primary melanoma is further divided into a) melanoma in situ when the atypical melanocytes are limited to the epidermis; b) invasive melanoma if it conquers the dermis. Invasive melanoma is historically classified according to clinical and histopathological characteristics into four major histological subtypes: superficial spreading melanoma, lentigo melanoma, nodular, and acral melanoma.

Get a Detailed Overview of the Evolving Metastatic Melanoma Market Trends @
https://www.delveinsight.com/report-store/metastatic-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Melanoma Market Key Facts
• Melanoma of the skin represents 5.6% of all new cancer cases in the US, with the rate of new cases of melanoma of the skin was 22.7 per 100,000 per year. The death rate was 2.3 per 100,000. These rates are age-adjusted and based on 2013-2017 cases and 2014-2018 deaths.
• As per the National Cancer Institute, in 2020, an estimated 6,850 persons died from melanoma in the United States. For melanoma of the skin, death rates are higher among the middle-aged and elderly. More than 65% of the deaths due to melanoma are between the age group of 55 to 85 years.
• According to the SEER estimates, 106,110 new cases of melanoma were observed in 2021. More than half of the new cases occurred in patients 60+ years of age.

Metastatic Melanoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic Melanoma pipeline therapies. It also thoroughly assesses the Metastatic Melanoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Metastatic Melanoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Learn How the Metastatic Melanoma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/report-store/metastatic-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Melanoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Metastatic Melanoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Metastatic Melanoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Metastatic Melanoma Epidemiology, Segmented as -
• Incident Cases of Melanoma in the 7MM [2019-2032]
• Age-specific Incident Cases of Melanoma in the 7MM [2019-2032]
• Mutation-specific (BRAF, MEK) Incident Cases of Melanoma in the 7MM [2019-2032]
• Stage-specific Incident Cases of Melanoma in the 7MM [2019-2032]
• Type-specific Incident Cases of Melanoma in the 7MM [2019-2032]
• Total Treated Cases of Melanoma in the 7MM [2019-2032]

Get Key Insights Into the Evolving Metastatic Melanoma Epidemiology Trends @
https://www.delveinsight.com/report-store/metastatic-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Melanoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Metastatic Melanoma market or expected to be launched during the study period. The analysis covers the Metastatic Melanoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Metastatic Melanoma drugs based on their sale and market share.

The report also covers the Metastatic Melanoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Metastatic Melanoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Metastatic Melanoma Market @
https://www.delveinsight.com/sample-request/metastatic-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Melanoma Therapeutics Analysis
The treatment of melanoma depends on its thickness, whether the cancer has spread, the stage, whether there are specific genetic changes in melanoma cells, the rate of Metastatic melanoma growth, and the person's overall health.

Over the past years, several therapies have been approved by the US FDA. Depending on the features of the tumor (location, stage, and genetic profile), the therapeutic options may be surgical resection, chemotherapy, radiotherapy, photodynamic therapy (PDT), immunotherapy, or targeted therapy. Yet, for individuals at Stages I-III, the most common treatment choice is surgical resection, and for solitary metastatic melanoma, metastasectomy remains the primary intervention.

Recently the US FDA approved OPDUALAG for patients with metastatic or inoperable melanoma, which consisted of two immunotherapy agents, relatlimab (anti-LAG-3) and nivolumab (anti-PD-1), which delayed time to cancer progression.

Several unmet needs are associated with melanoma, such as the need for prognostic biomarkers, raising awareness, better clinical research, and monitoring toxicity of immune checkpoints. To overcome these unmet needs, several prominent pharma and biotech giants are actively involved in developing therapies for Metastatic Melanoma. Among these key players, Evaxion Biotech stands out for advancing its Metastatic Melanoma drug candidates to the most advanced stage of clinical trials, specifically Phase II. This noteworthy progress underscores the collective dedication within the pharmaceutical industry to address the challenges posed by Metastatic Melanoma and emphasizes Evaxion Biotech's commitment to advancing innovative treatments for individuals affected by this aggressive disease.

On Feb. 16, 2024, U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor).

Metastatic Melanoma Companies Actively Working in the Therapeutics Market Include
In the dynamic landscape of Metastatic Melanoma, pharma and biotech companies such as Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others are leading the charge. Through their innovative research and development efforts, these companies are striving to advance the Metastatic Melanoma therapeutics outlook and treatment landscape.

Emerging and Marketed Metastatic Melanoma Therapies Covered in the Report Include:
• EVX 01: Evaxion Biotech
• IN 10018: InxMed
• AV MEL 1: AiVita Biomedical
And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/metastatic-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Melanoma Competitive Intelligence Analysis
4. Metastatic Melanoma Market Overview at a Glance
5. Metastatic Melanoma Disease Background and Overview
6. Metastatic Melanoma Patient Journey
7. Metastatic Melanoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Metastatic Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Melanoma Unmet Needs
10. Key Endpoints of Metastatic Melanoma Treatment
11. Metastatic Melanoma Marketed Therapies
12. Metastatic Melanoma Emerging Drugs and Latest Therapeutic Advances
13. Metastatic Melanoma Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Melanoma Market Outlook (In US, EU5, and Japan)
16. Metastatic Melanoma Companies Active in the Market
17. Metastatic Melanoma Access and Reimbursement Overview
18. KOL Views on the Metastatic Melanoma Market
19. Metastatic Melanoma Market Drivers
20. Metastatic Melanoma Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/metastatic-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.